Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab Monotherapy in Metastatic Colorectal Cancer
NCT00083616Phase 2Completed
- Sponsor
- Amgen
- Start
- Mar 2004
- Primary completion
- May 2007
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in colorectal cancer (CRC), sponsored by Amgen. Primary endpoint: Objective Tumor Response at 16 weeks. Started Mar 2004; status: completed.
02
Drugs
panitumumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00083616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00083616.